{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Episode 62: Apixaban Plasma Levels in Patients with HeartMate 3","description":"Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, \u201cApixaban plasma levels in patients with HeartMate 3 support.\u201d As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom\u2019s work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what clinical practices might need to change if introducing apixaban Additional studies exploring DOACs in LVAD patients For the latest studies from JHLT, visit www.jhltonline.org\/current, or, if you\u2019re an ISHLT member, access your Journal membership at www.ishlt.org\/jhlt. Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients. Don\u2019t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org. ","author_name":"JHLT: The Podcast","author_url":"http:\/\/thejhlt.libsyn.com\/website","html":"